Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Alterity Therapeutics showcased promising results at the AAN 2024 Annual Meeting for ATH434, their new treatment for Parkinson’s Disease and Multiple System Atrophy (MSA), highlighting its ability to improve motor skills and reduce brain iron. Data from their Phase 2 clinical trial indicated potential disease-modifying effects, including a correlation between elevated plasma Neurofilament Light Chain levels and disease severity. Findings from the bioMUSE natural history study also supported the use of NfL as a promising biomarker for tracking MSA progression.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
